Trimethoprim-sulfamethoxazole exacerbates posthypoxic action myoclonus in a patient with suspicion of Pneumocystis jiroveci infection

Infection

Volumn 32, Issue 3, 2004, Pages 176-178

  Jundt, F ^a   Lempert, T ^a   Dorken B ^a   Pezzutto, A ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; PIRACETAM; VALPROIC ACID;

ANAPHYLAXIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; CORRELATION ANALYSIS; DISEASE EXACERBATION; DRUG MEGADOSE; EXPERIENCE; HUMAN; LABORATORY TEST; LANCE ADAMS SYNDROME; MYOCLONUS; PNEUMOCYSTIS; PNEUMOCYSTIS JIROVECI; PNEUMONIA; SIDE EFFECT; STATISTICAL SIGNIFICANCE;

ANOXIA; ANTI-INFECTIVE AGENTS; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED; MYOCLONUS; PNEUMOCYSTIS; PNEUMONIA, PNEUMOCYSTIS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 2942589246     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-004-3011-6     Document Type: Article

References (27)

1. Stringer JR, Beard CB, Miller RF, Wakefield AE: A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerg Infect Dis 2002; 8: 891-896.
2. Masur H: Prevention and treatment of Pneumocystis pneumonia. N Engl J Med 1992; 327: 1853-1880.
3. Walzer PD: Pneumocystis carinii infection. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL (eds): Harrison's principles of internal medicine. McGraw-Hill, 2001, pp 1182-1185.
4. Gordin FM, Simon GL, Wofsy CB, Mills J: Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1984; 100: 495-499.
5. Salter AJ: Trimethoprim-sulfamethoxazole: an assessment of more than 12 years of use. Rev Infect Dis 1982; 4: 196-236.
6. See D, Mumford JM: Trimethoprim/sulfamethoxazole-induced toxic epidermal necrolysis. Ann Phamacother 2001; 35: 694-697.
7. Marinella MA: Trimethoprim-induced hyperkalemia: an analysis of reported cases. Gerontology 1999; 45: 209-212.
8. Dickson HG: Trimethoprim-sulphamethoxazole and thrombocytopenia. Med J Aust 1978; 2: 5-7.
9. Liu LX, Seward SJ, Crumpacker CS: Intravenous trimethoprim- sulfamethoxazole and ataxia. Ann Intern Med 1986; 104: 448.
10. Borucki MJ, Matzke DS, Pollard RB: Tremor induced by trimethoprim- sulfamethoxazole in patients with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1988; 109: 77-78.
11. Jaffe HS, Abrams DI, Ammann AJ, Lewis BJ, Golden JA: Complications of co-trimoxazole in treatment of AIDS-associated Pneumocystis carinii pneumonia in homosexual men. Lancet 1983; 2: 1109-1111.
12. Kremer I, Ritz R, Brunner F: Aseptic meningitis as an adverse effect of co-trimoxazole. N Engl J Med 1983; 308: 1481.
13. Lance JW, Adams RD: The syndrome of intention or action myoclonus as a sequel to hypoxic encephalopathy. Brain 1963; 86: 111-136.
14. Harper SJ: Posthypoxic myoclonus (the Lance-Adams syndrome) in the intensive care unit. Anaesthesia 1991; 46: 199-201.
15. Blindauer K: Myoclonus and its disorders. Mov Disord 2001; 19: 723-734.
16. Van Vleymen B, Van Zandijck M: Piracetam in the treatment of myoclonus: an overview. Acta Neurol Belg 1996; 96: 270-280.
17. Siber GR, Gorham CC, Ericson JF, Smith AL: Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole in children and adults with normal and impaired renal function. Rev Infect Dis 1982; 4: 566-578.
18. Shorvon S: Pyrrolidone derivatives. Lancet 2001; 358: 1885-1892.
19. Gram L, Drachman K: Valproate: an updated review. Acta Neurol Scand 1985; 72: 129-139.
20. Klotz U: The interaction potential of proton pump inhibitors. Verdauungskrankheiten 2002; 20: 26-31.
21. Masters PA, O'Bryan TA, Zurlo J, Miller DQ, Joshi N: Trimethoprim- sulfamethoxazole revisited. Arch Intern Med 2003; 163: 402-410.
22. Wormser GP, Keusch GT, Heel RC. Co-trimoxazole (trimethoprim- sulfamethoxazole): an updated review of its antibacterial activity and clinical efficacy. Drugs 1982; 24: 459-518.
23. England JM, Coles M: Effect of co-trimoxazole on phenylalanine metabolism in man. Lancet 1972; 2: 1341-1343.
24. Sze PY: Pharmacological effects of phenylalanine on seizure susceptibility: an overview. Neurochem Res 1989; 14: 103-111.
25. Coskun T, Karagoz T, Kalkanoglu S, Tokatli A, Ozalp I, Thony B, Blau N: Guanosine triphosphate cyclohydrolase I deficiency: a rare cause of hyperphenylalaninemia.Turk J Pediatr 1999; 41: 231-237.
26. Tanaka K, Yoneda M, Nakajima T, Miyatake T, Owada M: Dihydrobiopterin synthesis defect: an adult with diurnal fluctuation of symptoms. Neurology 1987; 37: 519-522.
27. Woody RC, Brewster MA: Adverse effect of trimethoprim-sulfamethoxazole in a child with dihydropteridine reductase deficiency. Dev Med Child Neurol 1990; 32: 639-642.